Anti-Hypertensive treatment of Nephrosclerosis in Elderly
Phase 4
Recruiting
- Conditions
- ephrosclerosis
- Registration Number
- JPRN-UMIN000004300
- Lead Sponsor
- Department of Nephrology, University of Tsukuba.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Hypertensive crisis 2. Hyperkalemia (serum potassium conc.>5.5mM) 3. renal failure (eGFR<30ml/min/1.73m2) 4. bilateral renal artery stenosis 5. newly onset of stroke (within 6 months just before entry) 6. severe congestive heart failure (more than NYHA class III) 7. liver dysfunction (AST/ALT concentration is 5 fold higher than normal range) 8. newly onset of acute myocardial infarction. 9. Malignancy 10. Patients who had severe adverse reactions by Ca channel blockers of RAS inhibitors. 11. Patients who are prescribed immunosuppressant or glucocorticoids. 12. Patients who are prescribed NSAIDs for long time (more than 2 weeks). 13. Patients whose doctors determined as inadequate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of estimated GFR before and after the treatment
- Secondary Outcome Measures
Name Time Method Change of following paparemters before and after the treatment (1) 1/serum creatinine concetration (2) Office blood pressure (3) heart rate (4) urinary albumin excretion (5) serum concentrations of BUN, cystatin C, and hs-CRP.